verified SJR 0,876 · Q2 • database Scopus / SJR & Web of Science indexed

Switzerland

workspace_premium Q2 — Medicine (miscellaneous) lock Subscription Unclaimed

American Journal of Cardiovascular Drugs

American Journal of Cardiovascular Drugs is a journal indexed in SJR in Medicine (miscellaneous) and Cardiology and Cardiovascular Medicine with an H index of 63. It has a price of 3190 €. It has an SJR impact factor of 0,876 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,876.

ISSN: 1175-3277

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Portal NPD menu_book Guidelines NPD

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

0,876 Q2

H-index 63

Tasa de Aceptación pie_chart

30% Selectiva

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

3.190 € Subscription

Ruta Non-OA 0 €

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

0,876

H-index

Docs (year)

Docs 3y

186

Total refs

3941

Cites 3y

525

Citable 3y

179

Cites/Doc 2y

2.8

Ref/Doc

46.36

Immediate OA

3190 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Cardiac Syndrome X

Vasopressin Receptor Antagonists

Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease

Coronary microvascular remodeling and ischaemia in hypertension

Contrast Nephropathy

Compared efficacy of three currently recommended antihypertensive strategies in Europe

Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative

Colesevelam

Cocaine Cardiotoxicity

Clinical Experience with Perindopril in Elderly Hypertensive Patients

Circadian Variations in Blood Pressure

Carnitine Palmitoyltransferase-I, a New Target for the Treatment of Heart Failure

SHOW MORE ARTICLES

Cardiovascular Risk in Patients with Early Renal Insufficiency

A Metabolic Approach to the Management of Ischemic Heart Disease

Cardiac Resynchronization Therapy in Patients with Chronic Heart Failure

Can Angiotensin Receptor Antagonists Prevent Restenosis After Stent Placement?

Calcium Channel Antagonists in the Treatment of Hypertension

Bosentan

Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study

Aortic Insufficiency

Antianginal Effects of Trimetazidine and Left Ventricular Function Improvement in Patients with Stable Angina Pectoris

Angiotensin II Receptor Antagonists Alone and Combined with Hydrochlorothiazide

Angiotensin Antagonism in Patients with Heart Failure

Acknowledgment

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.